IFN- And Fas Ligand Are Required for Graft-Versus-Tumor Activity Against Renal Cell Carcinoma in the Absence of Lethal Graft-Versus-Host Disease

Journal of Immunology - United States
doi 10.4049/jimmunol.179.3.1669
Full Text
Abstract

Available in full text

Date
Authors
Publisher

The American Association of Immunologists

Related search

Depletion of Naïve Lymphocytes With Fas Ligand Ex Vivo Prevents Graft-Versus-Host Disease Without Impairing T Cell Support of Engraftment or Graft-Versus-Tumor Activity

Biology of Blood and Marrow Transplantation
TransplantationHematology
2013English

Both Perforin and Fas Ligand Are Required for the Regulation of Alloreactive CD8+ T Cells During Acute Graft-Versus-Host Disease

Blood
BiochemistryImmunologyCell BiologyHematology
2005English

Graft-Versus-Host Disease

New England Journal of Medicine
Medicine
1991English

Graft Versus Host Disease

Bone Marrow Transplantation
TransplantationHematology
2000English

Graft Versus Host Disease

2020English

Intestinal Graft Versus Host Disease.

Journal of Clinical Pathology
MedicineForensic MedicinePathology
1991English

Etanercept in Graft-Versus-Host Disease

Bone Marrow Transplantation
TransplantationHematology
2000English

APRIL Levels Are Associated With Disease Activity in Human Chronic Graft-Versus-Host Disease

Haematologica
Hematology
2016English

Microbial Metabolites and Graft Versus Host Disease

American Journal of Transplantation
TransplantationAllergyImmunologyPharmacology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy